Michel Roger

Dr. Michel Roger


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SGSimon Gagnon
Simon Gagnon
SLSimon Lévesque
Simon Lévesque
BLBrigitte Lefebvre
Brigitte Lefebvre
ABAnne-Marie Bourgault
Anne-Marie Bourgault
ALAnnie-Claude Labbé
Annie-Claude Labbé
MRMichel Roger
Michel Roger
During the course of routine screening for vancomycin-resistant enterococci (VRE), we found six Enterococcus faecium isolates positive for vanA by PCR, but susceptible to vancomycin and teicoplanin by phenotypic testing. The aim of this study was to characterize the genetic composition of the Tn1546 vanA gene cluster of these isolates. The E. faecium isolates were characterized by antibiotic susceptibility, PFGE and structural analysis of the Tn1546 elements. Plasmids extracted from these isolates were used to determine the presence of the Tn1546 vanA gene cluster by PCR and the genomic organization of the deleted Tn1546 element by primer walking DNA sequencing. The vancomycin-susceptible vanA-positive E. faecium isolates showed three PFGE patterns, and were missing the vanR and vanS genes that are responsible for the activation of transcription of resistance genes. Primer walking sequencing revealed that these genes were completely deleted and that interruptions in the vanA cluster were in the vicinity of insertion sequence elements. The presence of vancomycin-susceptible vanA-positive E. faecium in clinical samples results from major deletions in the Tn1546 vanA operon. Our findings support the essential role of vanR and vanS for the expression of resistance to vancomycin in enterococci.

3 October 2014 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
IHI. Hardy
I. Hardy
BBB. Brenner
B. Brenner
PQPeter Kojo Quashie
Peter Kojo Quashie
RTR. Thomas
R. Thomas
CPC. Petropoulos
C. Petropoulos
MRMichel Roger
Michel Roger
Dolutegravir has been recently approved for treatment-naive and -experienced HIV-infected subjects, including integrase inhibitor (INI)-experienced patients. Dolutegravir is a second-generation INI that can overcome many prior raltegravir and elvitegravir failures. Here, we report the evolution of resistance to dolutegravir in a highly treatment-experienced patient harbouring the major N155H mutation consequent to raltegravir treatment failure. Genotypic and phenotypic analyses were done on longitudinal samples to determine viral resistance to INIs. Integrase amino acid sequence interactions with raltegravir and dolutegravir were assessed by molecular modelling and docking simulations. Five mutations (A49P, L68FL, T97A, E138K and L234V) were implicated in emergent dolutegravir resistance, with a concomitant severe compromise in viral replicative capacity. Molecular modelling and docking simulations revealed that dolutegravir binding to integrase was affected by these acquired dolutegravir mutations. Our findings identify a novel mutational pathway involving integrase mutations A49P and L234V, leading to dolutegravir resistance in a patient with the N155H raltegravir mutation.

16 January 2019 in JMIR Research Protocols
Verified
Journal Article
Open access
MEMariam El-Zein
Mariam El-Zein
FCFrançois Coutlée
François Coutlée
PTPierre-Paul Tellier
Pierre-Paul Tellier
MRMichel Roger
Michel Roger
EFEduardo Franco
Eduardo Franco
HGHITCH Study Group
HITCH Study Group
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Human papillomavirus (HPV) epidemiologic research has generally been individual-based, typically focusing on women, with couple-based research mostly consisting of cross-sectional assessment of prevalent HPV infection in both partners. Objective: The HPV Infection and Transmission among Couples through Heterosexual activity (HITCH) study was set up to investigate the transmissibility of HPV among young, recently-formed couples in Montreal, Canada. Methods: HITCH is a longitudinal investigation of HPV transmission in recently-formed heterosexual partnerships initiated within six-month pre-enrollment, a time at which considerable transmission is believed to occur. A total of 549 newly-formed dyads were recruited (2005-2011) from postsecondary institutions, including 502 young women and their male partner. An additional 46 males were enrolled at follow-up, as some women enrolled a subsequent partner at follow-up. Women aged 18-24 were followed for 24 months for acquisition of HPV types not present at enrolment, whereas men returned for a single follow-up visit at month 4, for a sum total of 3,361 clinic visits. The last follow-up visit occurred in January 2014. Extensive sociodemographic, sexual behavioural, and medical history data were collected every 2-4 months using computer-assisted self-administered questionnaires. Participants also provided genital, blood, oral, and hand specimens for HPV assessment. Results: Although in its early analysis stage, HITCH has produced important publications. Findings from HITCH have increased available knowledge about the natural history of HPV transmission and its determinants, provided further evidence regarding oral-oral and oral-genital routes of HPV transmission, and supplied empirically valid epidemiological parameters of HPV transmission to assist mathematical modelers in health economic assessments. HITCH data were made available to several multi-study collaborations evaluating new HPV detection assays and evidence for-or-against HPV type replacement following the introduction of HPV vaccination. Conclusions: HITCH will continue to offer a unique resource for research on HPV transmission. We welcome any opportunities for collaboration. For more information, researchers are invited to contact the principal investigator at eduardo.franco@mcgill.ca. Clinical Trial: NA

19 August 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Bluma BrennerBluma Brenner
Bluma Brenner
RIRuxandra-Ilinca Ibanescu
Ruxandra-Ilinca Ibanescu
NONathan Osman
Nathan Osman
ECErnesto Cuadra-Foy
Ernesto Cuadra-Foy
MOMaureen Oliveira
Maureen Oliveira
TGThe Montreal Primary HIV Infection (PHI) Cohort Study Group
The Montreal Primary HIV Infection (PHI) Cohort Study Group
Phylogenetics has been advanced as a structural framework to infer evolving trends in the regional spread of HIV-1 and guide public health interventions. In Quebec, molecular network analyses tracked HIV transmission dynamics from 2002–2020 using MEGA10-Neighbour-joining, HIV-TRACE, and MicrobeTrace methodologies. Phylogenetics revealed three patterns of viral spread among Men having Sex with Men (MSM, n = 5024) and heterosexuals (HET, n = 1345) harbouring subtype B epidemics as well as B and non-B subtype epidemics (n = 1848) introduced through migration. Notably, half of new subtype B infections amongst MSM and HET segregating as solitary transmissions or small cluster networks (2–5 members) declined by 70% from 2006–2020, concomitant to advances in treatment-as-prevention. Nonetheless, subtype B epidemic control amongst MSM was thwarted by the ongoing genesis and expansion of super-spreader large cluster variants leading to micro-epidemics, averaging 49 members/cluster at the end of 2020. The growth of large clusters was related to forward transmission cascades of untreated early-stage infections, younger at-risk populations, more transmissible/replicative-competent strains, and changing demographics. Subtype B and non-B subtype infections introduced through recent migration now surpass the domestic epidemic amongst MSM. Phylodynamics can assist in predicting and responding to active, recurrent, and newly emergent large cluster networks, as well as the cryptic spread of HIV introduced through migration.

17 July 2009 in AIDS
Verified
Journal Article
Closed access
JLJulie Lajoie
Julie Lajoie
JFJulie Fontaine
Julie Fontaine
CTCécile Tremblay
Cécile Tremblay
JRJean-Pierre Routy
Jean-Pierre Routy
JPJohanne Poudrier
Johanne Poudrier
MRMichel Roger
Michel Roger
Human leukocyte antigen-G is an important suppressor of the immune response, and HIV can modulate its expression. Longitudinal monitoring of soluble human leukocyte antigen-G plasma levels in patients with primary HIV infection undergoing different rates of disease progression showed that levels were elevated in the early phases of infection and remained high throughout follow-up in rapid progressors who responded to antiretroviral therapy but were restored to normal levels in the chronic phase of infection in both untreated normal progressors and long-term nonprogressors.

16 December 2019 in BMC Public Health
Verified
Journal Article
Open access
PDF file
NKNadine Kronfli
Nadine Kronfli
BLBlake Linthwaite
Blake Linthwaite
NSNancy Sheehan
Nancy Sheehan
JCJoseph Cox
Joseph Cox
IHIsabelle Hardy
Isabelle Hardy
MKMarina Klein
Marina Klein
Background: Migrants represent an increasing proportion of people living with HIV in many developed countries. We aimed to describe the HIV care cascade and baseline genotypic resistance for newly diagnosed asylum seekers referred to the McGill University Health Centre (MUHC) in Montreal, Quebec, Canada. Methods: We conducted a retrospective cohort study of patients linked to the MUHC from June 1, 2017 to October 31, 2018. We calculated the median time (days; interquartile range (IQR)) from: 1) entry into Canada to immigration medical examination (IME) (i.e. HIV screening); 2) IME to patient notification of diagnosis; 3) notification to linkage to HIV care (defined as a CD4 or viral load (VL) measure); 4) linkage to HIV care to combination antiretroviral therapy (cART) prescription; and 5) cART prescription to viral suppression (defined as a VL < 20 copies/mL). We reviewed baseline genotypes and interpreted mutations using the Stanford University HIV Drug Resistance Database. We calculated the proportion with full resistance to > 1 antiretroviral. Results: Overall, 43% (60/139) of asylum seekers were newly diagnosed in Canada. Among these, 62% were late presenters (CD4 < 350 cells/μl), 22% presented with advanced HIV (CD4 < 200 cells/μl), and 25% with high-level viremia (VL > 100,000 copies/ml). Median time from entry to IME: 27 days [IQR:13;55]; IME to notification: 28 days [IQR:21;49]; notification to linkage: 6 days [IQR:2;19]; linkage to cART prescription: 11 days [IQR:6;17]; and cART to viral suppression: 42 days [IQR:31;88]; 45% were linked to HIV care within 30 days. One-fifth (21%) had baseline resistance to at least one antiretroviral agent; the K103 N/S mutation was the most common mutation. Conclusions: While the majority of newly diagnosed asylum seekers were late presenters, only 45% were linked to care within 30 days. Once linked, care and viral suppression were rapid. Delays in screening and linkage to care present increased risk for onward transmission, and in the context of 21% baseline resistance, consideration of point-of-care testing and immediate referral at IME screening should be made.